FDA nominee Heidi Overton pledges faster drug trials to keep US biotech competitive

Heidi Overton, President Trump's nominee for FDA commissioner, will appear before a Senate committee to outline her priorities for the agency.

She said the administration wants her to 'go fast,' arguing that lengthy and restrictive requirements for advanced therapies are driving investment toward China, where development is reportedly quicker and cheaper.

Overton pledged to build on the Operation Trailblazer initiative, working with career staff to streamline clinical trial processes and accelerate the delivery of new treatments to patients.